Login to Your Account

Will Broad Anti-VEGF Drug Compromise Safety?

Eyetech CEO Keeps Faith In Wake Of Lucentis Bomb

By Randall Osborne

Monday, June 6, 2005

The perhaps unreasonable power of preliminary data - especially when it's offered by an industry powerhouse - was proved once again late last month when mighty Genentech Inc. disclosed positive early figures from a Phase III trial with Lucentis against age-related macular degeneration (AMD).

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription